Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants. [PDF]
NeuropsychopharmacologyArikci D +10 more
europepmc +1 more source
<i>Correction to:</i> The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item, by Strickland, et al. Psychedelic Medicine 2024;2(1):33-43; doi: 10.1089/psymed.2023.0046. [PDF]
Psychedelic Med (New Rochelle)europepmc +1 more source
Comparing psychedelic and meditation experience reports with natural language processing. [PDF]
Sci RepKallio-Mannila K, Salmela R, Jylkkä J.
europepmc +1 more source
Adverse outcomes following psychedelic use in adolescents and adults: associations with age and personality traits. [PDF]
Child Adolesc Psychiatry Ment HealthSjöström D +2 more
europepmc +1 more source
The Promises and Pitfalls of Psychedelic Use Among Religious Leaders. [PDF]
Psychedelic Med (New Rochelle)Simonsson O, Goldberg SB.
europepmc +1 more source
Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders. [PDF]
Npj Ment Health ResOlash C +8 more
europepmc +1 more source
Psychedelic Therapy and the Role of Music: A Scoping Review of Quantitative Evidence on Subjective and Objective Outcomes. [PDF]
Brain BehavRowe T +4 more
europepmc +1 more source
A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder. [PDF]
Brain SciSrivastava AB, Gold MS.
europepmc +1 more source
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression. [PDF]
J PsychopharmacolBrudner RM +11 more
europepmc +1 more source
From Science to Pleasure: Justifications of the Use of Classic Psychedelics in Finland. [PDF]
Nordisk Alkohol NarkTsupari M, Hupli A.
europepmc +1 more source